Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-14
2010-02-16
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S173100
Reexamination Certificate
active
07662783
ABSTRACT:
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 6071520 (2000-06-01), Noteborn et al.
patent: 7122635 (2006-10-01), Brooks et al.
patent: 2004/0224896 (2004-11-01), Brooks
patent: WO-00-40597 (2000-07-01), None
patent: WO-00-59532 (2000-10-01), None
patent: WO-2004-073649 (2004-02-01), None
National Cancer Institute, “Radiation Therapy”, www.cancer.gov.
Akalu , A. et al., “Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin,” Cancer Res. 67(9):4353-4363 (2007).
Gonzalez, A. et al., “Complex interactions between the laminin alpha 4 subunit and integrins egulate endothelial cell behavior in vitro and angiogenesis in vivo,” PNAS USA 99(25):16075-16080 (2002).
Kikkawa, Y. et al., “Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. Laminin-10/11 mediates cell adhesion through integrin alpha3 beta1,” J. Biol. Chem. (online), Am. Soc. Biochem. Mol. Biol., 273 (25):15854-15859 (1998).
Kurkinen, M. et al., “In vitro synthesis of laminin and entactin polypeptides,” J. Biol. Chem. 258(l0):6543-6548 (1983).
EP04758409.9 Supp EP Search Report dated Jul. 19, 2007.
Amstutz, et al., “In vitro display technologies: novel developments and applications,” Curr. Op. Biotech. 12:400-405 (2001).
Auerbach, R. et al., “Angiogenesis Assays: A Critical Overview,” Clin. Chem. 49(1):32-40 (2003).
Auerbach, R. et al., “Angiogenesis assays: Problems and pitfalls,” Cancer Metastasis Rev. 19:167-172 (2000).
Battegay, E.J., “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” J. Mol. Med. 73:333-346 (1995).
Blood, C.H. et al., “Tumor interactions with the vasculature: angiogenesis and tumor metastasis,” Biochim. Biophys. Acta. 1032:89-118 (1990).
Brooks, P. et al., “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,” Cell 79:1157-1162 (1994).
Brooks, P. et al., “Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity,” Cell 92:391-400 (1998).
Brooks, P. et al., “Antiintegrin αvβ3blocks human breast cancer growth and angiogenesis in human skin,” J. Clin. Invest. 96:1815-1822 (1995).
Burgess, W.H. et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” J. Cell. Biol. 111:2129-2138 (1990).
Engel, J., “Versatile cololagens in invertebrates,” Science 277:1785-1786 (1997).
Fischer, C., “Principles and Therapeutic Implications of Angiogenesis, Vasculogenesis and Arteriogenesis,” HEP 176(11):157-212 (2006).
Gordon et al., “The contribution of collagenous proteins to tissue-specific matrix assemblies,” Curr. Op. Cell Biol. 2:833-838 (1990).
Green et al., PNAS USA 100:1010-1015 (2003).
Guo et al., “In vitro evolution of amphioxus insulin-like peptide to mammalian insulin,” Biochem. 41:10603-10607 (2002).
Guo, H. et al., “Protein tolerance to random amino acid change,” PNAS USA 101(25):9205-9210 (2004).
Hangai et al., “Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis,” Am. J. Pathology 161(4):1429-1437 (2002).
Heeley, R.P., Endocr. Res. 28:217-229 (2002).
Ingham et al., “Type 1 collagen contains at least 14 cryptic fibronectin binding sires of similiar affinity,” Arch. Biochem. Biophys. 407:217-223 (2002).
Jo, N. et al., “Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization,” Mol. Vision 12:1243-1249 (2006).
Jones, D.T., “Critically assessing the state-of-the-art in protein structure prediction,” Pharmacogenomics J. 1:126-134 (2001).
Kim, J. et al., “Inhibition of Angiogenesis and Angiogenesis-dependent Tumor Growth by the Cryptic Kringle Fragments of Human Apolipoprotein(a)*,” J. Biol. Chem. 278:29000-29008 (2003).
Kim, S. et al., “Regulation of Angiogenesis In Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin,” Am. J. Path. 156:1345-1362 (2000).
Kurschat, P., “Mechanisms of Metastasis,” Clin. Exp. Dermatol. 25:482-489 (2000).
Lazar, E. et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol. 8:1247-1252 (1988).
Liljeblad et al., “Analaysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance,” Glycoconjugate J. 17:323-329 (2000).
Liotta, L. A. et al., “Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation,” Cell 65:327-336 (1991).
Qin, X. et al., “Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4*,” JBC 273(36):23509-23516 (1998).
Roskelley, C.D. et al., “A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression,” Curr. Op. Cell Biol. 7:736-747 (1995).
Skolnick, J. et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotech. 18:34-39 (2000).
Staton, C.A. et al., “Current methods for assaying angiogenesis in vitro and in vivo,” Intl J. Exp. Path. 85:233-248 (2004).
Steffensen et al., “Human fibronectin and MMp-2 collagen binding domains competer for collagen binding site and modify cellular activation of MMP-2,” Matrix Biol. 21:399-414 (2002).
Stephanopoulos, G., “Metabolic engineering by genome shuffling,” Nature Biotech. 20(7):666-668 (2002).
Tani et al., “In vitro selection of fibronectin gain-of-function mutations,” Biochem. J. 365:287-294 (2002).
Tosatto, S.C.E. et al., “Large-Scale Prediction of Protein Structure and Function from Sequence,” Curr. Pharma. Des. 12:2067-2086 (2006).
Varner et al., Cell Adh. Commun. 3:367-374 (1995).
Weidner, N. et al., “Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma,” J. Natl. Cancer Inst. 84:1875-1887 (1992).
Weidner, N. et al., “Tumor Angiogensis and Metastasis-Correlation in Invasive Breast Carcinoma,” N. Engl. J. Med. 324:1-7 (1991).
Wyckoff, J., “A Critical Step in Metastasis: In Vivo Analysis of Intravasation at the Primary Tumor,” Cancer Res. 60:2504-2511 (2000).
Xu et al., “Generatio of monoclonal antibodies to cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo,” J. Cell Biol. 154(5):1069-1079 (2001).
Xu et al., “Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo,” J. Cell Biol. 154(5):1069-1079 (
Akalu Abebe
Brooks Peter C.
Roth Jennifer
New York University
Tate Christopher R.
Teller Roy
Wilson Sonsini Goodrich & Rosati
LandOfFree
CLK-peptide and SLK-peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CLK-peptide and SLK-peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CLK-peptide and SLK-peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196252